Longer duration of catheter patency, but similar infection rates with internal jugular vein versus iliac vein tunneled cuffed hemodialysis catheters: a single-center retrospective analysis

International Urology and Nephrology
Lihua WangXueqing Bi

Abstract

Although tunneled cuffed catheters (TCCs) are widely used in hemodialysis, little is known about their complications in elderly patients with hemodialysis. Furthermore, there is no report about which vessel access, either jugular or iliac vein, is superior for elderly patients requiring TCCs. In the present study, we reviewed the clinical parameters of 127 patients aged over 65 years with 207 new TCC placements and measured the incidence of catheter patency, infection, dysfunction, and survival of TCCs. We found that the average primary catheter patency was substantially shorter in iliac vein TCCs than in internal jugular vein TCCs (373 vs. 641 catheter-days). Patients with iliac vein TCCs underwent more frequent exchanges than those with internal jugular vein TCCs. Infection-free survival was similar for both groups (p = 0.748), but dysfunction-free survival was significantly poorer in iliac vein TCC group than that in internal jugular vein TCC group (p = 0.001). Age and previous catheter placement were the independent risk factors for TCCs survival. Taken together, our results suggested that iliac vein TCCs present an increased risk of dysfunction compared to internal jugular vein TCCs in elderly hemodialysis patients.

References

Dec 10, 1999·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·T F Saad
Sep 29, 2001·Kidney International·R K DhingraF K Port
Feb 19, 2002·Kidney International·Zipporah KrishnasamiMichael Allon
Feb 20, 2002·Seminars in Dialysis·J Work
Feb 20, 2002·Seminars in Dialysis·T F Saad
May 15, 2003·Scandinavian Journal of Urology and Nephrology·Chamberlain I ObialoLinda F Lebon
Mar 3, 2004·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Christopher V PooleMichael Allon
May 11, 2005·Kidney International·Bertrand L Jaber
Jul 16, 2005·Clinica Chimica Acta; International Journal of Clinical Chemistry·Ori RogowskiShlomo Berliner
Feb 24, 2006·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Michael AllonSteve J Schwab
Mar 15, 2006·Kidney & Blood Pressure Research·V CampeanK Amann
Mar 23, 2006·Seminars in Dialysis·Orfeas LiangosBertrand L Jaber
Apr 22, 2006·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Christoph BetzHelmut Geiger
Jul 4, 2006·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·UNKNOWN Vascular Access Work Group
Jul 27, 2006·International Urology and Nephrology·Adrian CovicDavid J A Goldsmith
May 25, 2007·International Urology and Nephrology·Theofanis Apostolou
Oct 19, 2007·Clinical Journal of the American Society of Nephrology : CJASN·Matthew J OliverCharmaine E Lok
Sep 17, 2008·International Urology and Nephrology·Nikolaos BessiasVassilios Andrikopoulos
Oct 22, 2008·Kidney & Blood Pressure Research·Michele BuemiAlessio Sturiale
Nov 13, 2008·Seminars in Dialysis·Micah R Chan
Feb 23, 2010·The Journal of Vascular Access·Rosilene Motta EliasJoão Egidio Romão
Jan 24, 2012·The Journal of Vascular Access·Almudena Martín-PeñaUNKNOWN Spanish Network for Research in Infectious Diseases
Sep 1, 2012·Kidney International·Peter G BlakeMatthew J Oliver
Feb 25, 2014·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Daniel W Coyne

❮ Previous
Next ❯

Citations

Jul 3, 2017·Blood Purification·Stefan BüttnerChristoph Betz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alternative Complement Pathway

The Alternative Complement Pathway is part of the innate immune system, and activation generates membrane attack complexes that kill pathogenic cells. Discover the latest research on the Alternative Complement Pathway.